Bisphosphonates in the treatment of glucocorticoid-lnduced osteoporosis

Frontiers of Hormone Research

Volumn 30, Issue , 2002, Pages 150-164

  Doga, M ^a   Bonadonna, S ^a   Burattin, A ^a   Carpinteri, R ^a   Manelli, F ^a   Giustina, A ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Endocrine Section   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

ANIMAL; BONE DENSITY; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; FRACTURE; HUMAN; OSTEOPOROSIS; REVIEW;

ANIMALS; BONE DENSITY; DIPHOSPHONATES; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 0036365099     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (43)

1. Heish H: Bisphosphonates. Drugs 1991;42:919-944.
2. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OHN: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-1271.
3. Watts NB, Harris ST, Genant HK, Wasnich R, Miller PD: Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
4. Blomaa I, Blomqvist C, Porkka I, Lamberg-Allardt C, Borgstrom GH: Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 1987;8(suppl):53-56.
5. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S: Oral clodronate decreases skeletal morbidity in patients with bone metastases for breast cancer: Double-blind controlled trial. J Clin Oncol 1993;11:59-65.
6. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P: Structure-activity relationship of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
7. Geddes AD, D'Souza SM, Ebetino H, Ibbotson KI: Bisphosphonates: Structure-activity relationship and therapeutic implications. Bone Miner Res Annu 1994;8:265-306.
8. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al: Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095-2105.
9. Schenk R, Eggli P, Felix H, Rosini S: Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-349.
10. Muhlbauer RC, Russel RGG, Williams DA, Heish H: The effect of disphosphonates polyphosphates, and calcitonin on immobilisation osteoporosis in rats. Eur J Clin Invest 1971;1:336-344.
11. Jee WSS, Black HI, Gotcher JE: Effect of dichloromethane diphosphonate on cortisol-induced bone loss in young adult rabbits. Clin Orthop 1981;156:39-51.
12. Wink CS, Onge MST, Parker B: The effects of dichloromethylene bisphosphonate on osteoporotic femora of adult castrate male rats. Acta Anat 1985;124:117-121.
13. Belena R, Markatos A, Gentile M, Musarachia P, Seedor JG, Rodan GA, Yamamoto M: The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat: Comparison between effects on tibiae and vertebrae. Bone 1993;14:499-504.
14. Toolan BG, Balena R, Shea M, Markatos Amyers ER, Lee SC, et al: The effects of two-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength on ovariectomized non-human primates. J Clin Invest 1993;92:2577-2586.
15. Thompson DD, Seedor JG, Quartuccio H, Solomon H, Fioravanti C, Davidson J, et al: The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992;7:951-960.
16. Thompson DD, Seedor JG, Weinreb M, Rosini S, Rodan GA: Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res 1990;5:279-286.
17. Galasko CSB, Samuel AW, Rushton S, Lacey E: The effect of prostaglandin synthesis inhibitors and diphosphonates on tumor-mediated osteolysis. Br J Surg 1980;67:493-946.
18. Marlodaun RR, Thornton KS, Sica DA, D'Souza SM, Flora I, et al: The effect of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 1983;35:512-519.
19. Bassani D, Sabatini M, Seariziam E, De Francesco I, Coccioli G, et al: Bone invasion by Walker 256 carcinoma, line A, in young and adult rats, effects of etidronate. Oncology 1990;17:160-169.
20. Guaitani A, Sabatini M, Coccioli D, Cristina S, Garattini S, et al: An experimental rat model of local bone cancer invasion and its responsiveness to ethane 1 hydroxy-1,1-bis(phosphonate) Cancer Res 1985;45:2200-2209.
21. Sietsema WR, Ebetino FH, Salvagna AM, Bevan JA: Antiresorptive dose-response relationship across three generations of bisphosphonates. Drugs Under Exp Clin Res 1989;15:389-396.
22. Muhlblatter RC, Statzer A, Schenk R, Janner M, Fleish H, Bosies E, et al: 1-Hydroxy3-(methylpentylamino) propylidene bisphosphonate (BM 21,0955), a potent new inhibitor of bone resorption. J Bone Miner Res 1991;6:1003-1011.
23. Fast DK, Felix R, Dowse C, Newman WF, Fleish H: The effects of disphosphonates on growth and glycolysis of connective tissue cells in culture. Biochem J 1978;172:97-107.
24. 14C-1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 1984;36:108-113.
25. Carano A, Teitelbaum SL, Konsek JD, Schlesingen PH, Blair HC: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:465-471.
26. Sato M, Grasser W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
27. Russel SGG, Kanis JA: Tumor-Induced Hypercalcemia and Its Management. Royal Society of Medicine International Congress and Symposium Series 176. London, RSM, 1991.
28. Sahni M, Guenther HL, Melsch H, Collin P, Martin TJ: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-2011.
29. Hughes DE, MacDonald BR, Russell RGG, Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83: 1930-1935.
30. Boonekamp PM, van der Wee Pals LJA, van Wil van Lennep MLL, Thesing CW, Hijvoct OLM: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
31. Plosker GL, Goa KL: Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-982.
32. Herrala J, Puolijoki H, Liippo K, Raitio M, Tala E, Nieminen MM: Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone 1998;22:577-582.
33. Struys A, Snelder AA, Mulder H: Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99: 235-242.
34. Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C: A double-blind placebo-controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Thorax 1998;53:351-356.
35. Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH: 36-Month intermittent cyclical etidronate treatment in patients with established corticosteroid-induced osteoporosis. J Rheumatol 1999; 26:1545-1549.
36. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B: Randomized trial of effect of cyclical etidronate in the prevention of corticosteroidinduced bone loss. J Clin Endocrinol Metab 1998;83:1128-1133.
37. Diamond T, McGuigan L, Barbagallo S, Bryant C: Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 1995;98:459-463.
38. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste Marie LG, Tenenhouse A, Chines AA: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-387.
39. Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1998;23:143-146.
40. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-299.
41. Wallach S, Cohen S, Reid DM, Hughes RA, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-285.
42. Eastell R, Devogelaer JP, Peel NFA, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RGG: Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11:331-337.
43. Manelli F, Giustina A: Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000;11: 79-83.